Please try another search
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Terry C. Vance | 63 | 2011 | Independent Director |
Bruce Leonard Andrews Carter | 78 | 2013 | Independent Non-Executive Chairman |
Jay R. Luly | 65 | 2003 | President, CEO & Director |
Kristine Peterson | 62 | 2017 | Independent Director |
Mark G. Foletta | 60 | 2020 | Independent Director |
Yujiro S. Hata | 47 | 2008 | Independent Director |
Lesley Russell | 60 | 2016 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review